1.
Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study.
Campochiaro Peter A, Channa Roomasa, Berger Brian B, Heier Jeffrey S, Brown David M, Fiedler Ulrike et al.
Am J OphthalmolApr 201386 citationsClinical Trial
MP0112, a novel anti-VEGF drug, showed prolonged vision and edema improvement in DME patients, but initial formulations caused inflammation. Impurities were identified and removed for future trials.